Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

OBJECTIVE: To assess the prophylactic efficacy of aspirin and a high-dose antioxidant vitamin combination in patients with peripheral arterial disease (PAD) in terms of reduction of the risk of a first vascular event (myocardial infarction, stroke, vascular death) and critical limb ischaemia. DESIGN: Randomized, placebo-controlled, double-blind clinical trial with 2 x 2 factorial design. SETTING: Thirty-seven European angiology/vascular medicine units. SUBJECTS: A total of 366 outpatients with stage I-II PAD documented by angiography or ultrasound, with ankle/brachial index <0.85 or toe index <0.6; 210 patients completed the follow-up. INTERVENTIONS: Four treatment groups: (i) oral aspirin (100 mg daily), (ii) oral antioxidant vitamins (600 mg vitamin E, 250 mg vitamin C and 20 mg beta-carotene daily), (iii) both or (iv) neither, given for 2 years. MAIN OUTCOME MEASURE: Major vascular events (cardiovascular death, myocardial infarction or stroke) and critical leg ischaemia. RESULTS: Seven of 185 patients allocated aspirin and 20 of 181 allocated placebo suffered a major vascular event (risk reduction 64%, P = 0.022); five and eight patients, respectively, suffered critical leg ischaemia (total 12 vs. 28, P = 0.014). There was no evidence that antioxidant vitamins were beneficial (16/185 vs. 11/181 vascular events). Neither treatment was associated with any significant increase in adverse events. Inclusion of this trial in a meta-analysis of other randomized trials of anti-platelet therapy in PAD makes the overall results highly significant (P < 0.001) and suggests that low-dose aspirin reduces the incidence of vascular events by 26%. CONCLUSIONS: For the first time direct evidence shows that low-dose aspirin should routinely be considered for PAD patients, including those with concomitant type 2 diabetes.

Original publication

DOI

10.1111/j.1365-2796.2006.01763.x

Type

Journal article

Journal

J Intern Med

Publication Date

03/2007

Volume

261

Pages

276 - 284

Keywords

Aged, Aspirin, Double-Blind Method, Female, Humans, Ischemia, Leg, Male, Peripheral Vascular Diseases, Platelet Aggregation Inhibitors, Treatment Outcome